CNS repurposing - Potential new uses for old drugs: Examples of screens for Alzheimer's disease, Parkinson's disease and spasticity

Drug repositioning: identifying and developing new uses for existing drugs

Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237 · see citing works

Untitled work

Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194 · see citing works

An analysis of the attrition of drug candidates from four major pharmaceutical companies

Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450 · see citing works

α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

Bartels, T., Choi, J. G., & Selkoe, D. J. (2011) · Nature · doi:10.1038/nature10324 · Cited by 1,263 · cited 1× · see citing works

Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers

Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3432-04.2004 · Cited by 954 · see citing works

Etiology and pathogenesis of Parkinson's disease

Schapira, A. H. V., & Jenner, P. G. (2011) · Movement Disorders · doi:10.1002/mds.23732 · Cited by 659 · see citing works

The Synucleinopathies: Twenty Years On

Goedert, M., Jakes, R., & Spillantini, M. G. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-179005 · Cited by 566 · see citing works

Neurotoxin-based models of Parkinson's disease

Bové, J., & Perier, C. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.10.057 · Cited by 508 · see citing works

Drug development in Alzheimer’s disease: the path to 2025

Cummings, J., Aisen, P. S., DuBois, B., Frölich, L., Jack, C. R., Jones, R. W., Morris, J. C., Raskin, J., Dowsett, S. A., & Scheltens, P. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0207-9 · Cited by 459 · see citing works

Glutamate in CNS disorders as a target for drug development: an update

Parsons, C. G., Danysz, W., & Quack, G. (1998) · Drug News & Perspectives · doi:10.1358/dnp.1998.11.9.863689 · Cited by 438 · see citing works

Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human α‐synuclein

Lakso, M., Vartiainen, S., Moilanen, A., Sirviö, J., Thomas, J. H., Nass, R., Blakely, R., & Wong, G. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01809.x · Cited by 398 · see citing works

Amyloid-β and tau complexity — towards improved biomarkers and targeted therapies

Polanco, J. C., Li, C., Bodea, L., Martínez‐Mármol, R., Meunier, F. A., & Götz, J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.162 · Cited by 374 · see citing works

A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (“Line 61”) Mice

Chesselet, M.-F., Richter, F., Zhu, C., Magen, I., Watson, M. B., & Subramaniam, S. R. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0104-2 · Cited by 346 · see citing works

α-Synuclein and dopamine at the crossroads of Parkinson's disease

Venda, L. L., Cragg, S. J., Buchman, V. L., & Wade‐Martins, R. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.09.004 · Cited by 288 · see citing works

In silico repositioning of approved drugs for rare and neglected diseases

Ekins, S., Williams, A. J., Krasowski, M. D., & Freundlich, J. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.016 · Cited by 288 · see citing works

Drosophila melanogaster in the Study of Human Neurodegeneration

Hirth, F. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791556104 · Cited by 236 · see citing works

Drug repositioning for orphan diseases

Sardana, D., Zhu, C., Zhang, M., Gudivada, R. C., Yang, L., & Jegga, A. G. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr021 · Cited by 228 · see citing works

A bibliometric review of drug repurposing

Baker, N., Ekins, S., Williams, A. J., & Tropsha, A. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.018 · Cited by 206 · see citing works

Applications of chemogenomic library screening in drug discovery

Jones, L. H., & Bunnage, M. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.244 · Cited by 192 · see citing works

Neurodegenerative processes in Huntington's disease

Bano, D., Zanetti, F., Mende, Y., & Nicotera, P. (2011) · Cell Death and Disease · doi:10.1038/cddis.2011.112 · Cited by 169 · see citing works

A Novel “Molecular Tweezer” Inhibitor of α-Synuclein Neurotoxicity in Vitro and in Vivo

Prabhudesai, S., Sinha, S., Attar, A., Kotagiri, A., Fitzmaurice, A., Lakshmanan, R., Ivanova, M., Loo, J. A., Klärner, F., Schrader, T., et al. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0105-1 · Cited by 165 · see citing works

Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper

Otero‐Romero, S., Sastre‐Garriga, J., Comi, G., Hartung, H.-P., Sørensen, P. S., Thompson, A. J., Vermersch, P., Gold, R., & Montalbán, X. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516643600 · Cited by 163 · see citing works

Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons

Rocha, E. M., Smith, G. A., Park, E. Y. H., Cao, H., Brown, E., Hayes, M. A., Beagan, J. A., McLean, J. R., Izen, S. C., Perez-Torres, E., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.09.009 · Cited by 157 · see citing works

Inflammatory Mediators Induced by Amyloid-Beta in the Retina and RPE In Vivo: Implications for Inflammasome Activation in Age-Related Macular Degeneration

Liu, R. T., Gao, J., Cao, S., Sandhu, N., Cui, J. Z., Chou, C. L., Fang, E., & Matsubara, J. A. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-10849 · Cited by 152 · see citing works

Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease

Sahoo, A. K., Dandapat, J., Dash, U. C., & Kanhar, S. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.12.015 · Cited by 147 · see citing works

Structural insights on physiological functions and pathological effects of ±‐synuclein

Bisaglia, M., Mammi, S., & Bubacco, L. (2008) · The FASEB Journal · doi:10.1096/fj.08-119784 · Cited by 140 · see citing works

Learning from the past and looking to the future: emerging perspectives for improving the treatment of psychiatric disorders

Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132 · see citing works

Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers

Ugalde, C. L., Finkelstein, D. I., Lawson, V. A., & Hill, A. F. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13772 · Cited by 92 · see citing works

Rehabilitation medicine: 3. Management of adult spasticity.

Satkunam, L. E. (2003) · PubMed · Cited by 89 · see citing works

Multifactorial sleep disturbance in Parkinson's disease

Albers, J. A., Chand, P., & Anch, A. M. (2017) · Sleep Medicine · doi:10.1016/j.sleep.2017.03.026 · Cited by 89 · see citing works

A Brighter Side to Thalidomide: Its Potential Use in Immunological Disorders

Millrine, D., & Kishimoto, T. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.02.006 · Cited by 87 · see citing works

Applications of High Content Screening in Life Science Research

Zock, J. M. (2009) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620709789383277 · Cited by 85 · see citing works

Computational drug repositioning for rare diseases in the era of precision medicine

Delavan, B., Roberts, R. A., Huang, R., Bao, W., Tong, W., & Liu, Z. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.10.009 · Cited by 84 · see citing works

High-throughput analysis of behavior for drug discovery

Alexandrov, V., Brunner, D., Hanania, T., & Leahy, E. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.11.047 · Cited by 81 · see citing works

α-Synuclein Budding Yeast Model: Toxicity Enhanced by Impaired Proteasome and Oxidative Stress

Sharma, N., Brandis, K. A., Herrera, S. K., Johnson, B. E., Vaidya, T., Shrestha, R., & DebBurman, S. K. (2006) · Journal of Molecular Neuroscience · doi:10.1385/jmn:28:2:161 · Cited by 81 · see citing works

Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders

Lee, H.-M., & Kim, Y. (2016) · Schizophrenia Research and Treatment · doi:10.1155/2016/6378137 · Cited by 80 · see citing works

TDP-1/TDP-43 Regulates Stress Signaling and Age-Dependent Proteotoxicity in Caenorhabditis elegans

Vaccaro, A., Tauffenberger, A., Ash, P. E. A., Carlomagno, Y., Petrucelli, L., & Parker, J. A. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002806 · Cited by 79 · see citing works

Organotypic cultures as tools for optimizing central nervous system cell therapies

Daviaud, N., Garbayo, E., Schiller, P. C., Pérez‐Pinzón, M. A., & Montero‐Menei, C. N. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.07.012 · Cited by 78 · see citing works

The effect of α‐synuclein knockdown on MPP+ toxicity in models of human neurons

Fountaine, T. M., Venda, L. L., Warrick, N., Christian, H., Brundin, P., Channon, K. M., & Wade‐Martins, R. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06527.x · Cited by 78 · see citing works

MPTP: an industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson's disease.

Kopin, I. J. (1987) · Environmental Health Perspectives · doi:10.1289/ehp.877545 · Cited by 77 · see citing works

Enhancing the Promise of Drug Repositioning through Genetics

Pritchard, J.-L., O’Mara, T. A., & Glubb, D. M. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00896 · Cited by 73 · see citing works

Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways

Anandhan, A., Rodríguez‐Rocha, H., Bohovych, I., Griggs, A. M., Zavala-Flores, L. M., Reyes‐Reyes, E. M., Seravalli, J., Stanciu, L., Lee, J., Rochet, J., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.11.018 · Cited by 72 · see citing works

Methods used to study the oligomeric structure of G-protein-coupled receptors

Guo, H., An, S., Ward, R. J., Yang, Y., Liu, Y., Guo, X., Hao, Q., & Xu, T. (2017) · Bioscience Reports · doi:10.1042/bsr20160547 · Cited by 71 · see citing works

Perspectives on recent advances in the understanding and treatment of Parkinson's disease

Schapira, A. H., Agid, Y., Barone, P., Jenner, P., Lemke, M. R., Poewe, W., Rascol, O., Reichmann, H., & Tolosa, E. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02793.x · Cited by 69 · see citing works

Rotenone induces aggregation of γ-tubulin protein and subsequent disorganization of the centrosome: Relevance to formation of inclusion bodies and neurodegeneration

Diaz-Corrales, F. J. J., Asanuma, M., Miyazaki, I., Miyoshi, K., & Ogawa, N. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.01.044 · Cited by 67 · see citing works

Cancer Drug Development Using Drosophila as an in vivo Tool: From Bedside to Bench and Back

Yadav, A. K., Srikrishna, S., & Gupta, S. C. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.05.010 · Cited by 63 · see citing works

Methods of probing the interactions between small molecules and disordered proteins

Heller, G. T., Aprile, F. A., & Vendruscolo, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2563-4 · Cited by 62 · see citing works

Amyloid fibril formation by the glaucoma-associated olfactomedin domain of myocilin

Orwig, S. D., Perry, C. W., Kim, L., Turnage, K. C., Zhang, R., Vollrath, D., Schmidt-Krey, I., & Lieberman, R. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.016 · Cited by 55 · see citing works

Glaucoma progression associated with altered cerebral spinal fluid levels of amyloid beta and tau proteins

Nucci, C., Martucci, A., Martorana, A., Sancesario, G. M., & Cerulli, L. (2010) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2010.02452.x · Cited by 51 · see citing works

ADME-Guided Design and Synthesis of Aryloxanyl Pyrazolone Derivatives To Block Mutant Superoxide Dismutase 1 (SOD1) Cytotoxicity and Protein Aggregation: Potential Application for the Treatment of Amyotrophic Lateral Sclerosis

Chen, T., Benmohamed, R., Kim, J.-H., Smith, K., Amante, D. J., Morimoto, R. I., Kirsch, D. R., Ferrante, R. J., & Silverman, R. B. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2014277 · Cited by 50 · see citing works

MRZ-99030 – A novel modulator of Aβ aggregation: II – Reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice

Rammes, G., Gravius, A., Ruitenberg, M., Wegener, N., Chambon, C., Sroka, K., Jeggo, R., Staniaszek, L. E., Spanswick, D. C., O‘Hare, E., et al. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.12.037 · Cited by 50 · see citing works

Elevated amyloid β production in senescent retinal pigment epithelium, a possible mechanism of subretinal deposition of amyloid β in age-related macular degeneration

Wang, J., Ohno‐Matsui, K., & Morita, I. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.05.085 · Cited by 45 · see citing works

A chemical genomics approach to drug reprofiling in oncology: Antipsychotic drug risperidone as a potential adenocarcinoma treatment

Dilly, S. J., Clark, A. J., Marsh, A., Mitchell, D. A., Cain, R. M., Fishwick, C. W. G., & Taylor, P. C. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.042 · Cited by 40 · see citing works

α-Synuclein Fission Yeast Model: Concentration-Dependent Aggregation Without Plasma Membrane Localization or Toxicity

Brandis, K. A., Holmes, I. F., England, S. J., Sharma, N., Kukreja, L., & DebBurman, S. K. (2006) · Journal of Molecular Neuroscience · doi:10.1385/jmn:28:2:179 · Cited by 39 · see citing works

Treatment Options for Tauopathies

Karakaya, T., Fußer, F., Prvulovic, D., & Hampel, H. J. (2012) · Current Treatment Options in Neurology · doi:10.1007/s11940-012-0168-7 · Cited by 39 · see citing works

Measurement of the pharmacokinetics and pharmacodynamics of neuroactive compounds

Alavijeh, M. S., & Palmer, A. M. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.09.025 · Cited by 38 · see citing works

Drug repurposing for aging research using model organisms

Ziehm, M., Kaur, S., Ivanov, D. K., Ballester, P. J., Marcus, D., Partridge, L., & Thornton, J. M. (2017) · Aging Cell · doi:10.1111/acel.12626 · Cited by 38 · see citing works

Exploring patient and family involvement in the lifecycle of an orphan drug: a scoping review

Young, A., Menon, D., Street, J., Al‐Hertani, W., & Stafinski, T. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-017-0738-6 · Cited by 38 · see citing works

Drug Repositioning: Playing Dirty to Kill Pain

Bastos, L. F. S., & Coelho, M. M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0128-0 · Cited by 36 · see citing works

Intramuscular Neurotrophin-3 normalizes low threshold spinal reflexes, reduces spasms and improves mobility after bilateral corticospinal tract injury in rats

Kathe, C., Hutson, T. H., McMahon, S. B., & Moon, L. D. F. (2016) · eLife · doi:10.7554/elife.18146 · Cited by 36 · see citing works

Caenorhabditis elegans as a model system for identifying effectors of α-synuclein misfolding and dopaminergic cell death associated with Parkinson’s disease

Harrington, A. J., Knight, A. L., Caldwell, G. A., & Caldwell, K. A. (2011) · Methods · doi:10.1016/j.ymeth.2010.12.036 · Cited by 35 · see citing works

Fragments of HdhQ150 Mutant Huntingtin Form a Soluble Oligomer Pool That Declines with Aggregate Deposition upon Aging

Marcellin, D., Abramowski, D., Young, D., Richter, J., Weiss, A., Marcel, A., Maassen, J., Kauffmann, M., Bibel, M., Shimshek, D. R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044457 · Cited by 33 · see citing works

MRZ-99030 – A novel modulator of Aβ aggregation: I – Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD)

Parsons, C. G., Ruitenberg, M., Freitag, C. E., Sroka, K., Russ, H., & Rammes, G. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.12.038 · Cited by 31 · see citing works

Multiple Sclerosis

Gaby, A. R. (2013) · Global Advances in Health and Medicine · doi:10.7453/gahmj.2013.2.1.009 · Cited by 31 · see citing works

Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer’s disease

Parsons, C. G., & Rammes, G. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1313832 · Cited by 28 · see citing works

An Overview on the Role of α -Synuclein in Experimental Models of Parkinson’s Disease from Pathogenesis to Therapeutics

Javed, H., Kamal, M. A., & Ojha, S. K. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666160920160512 · Cited by 25 · see citing works

High-throughput screening in the C. elegans nervous system

Kinser, H. E., & Pincus, Z. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2016.06.001 · Cited by 24 · see citing works

Molecules that Disrupt Memory Circuits in Alzheimer’s Disease: The Attack on Synapses by Aβ Oligomers (ADDLs)

Klein, W. L., Lacor, P. N., Felice, F. G. D., & Ferreira, S. T. (2007) · Research and perspectives in neurosciences · doi:10.1007/978-3-540-45702-2_11 · Cited by 23 · see citing works

A Zebrafish Drug-Repurposing Screen Reveals sGC-Dependent and sGC-Independent Pro-Inflammatory Activities of Nitric Oxide

Wittmann, C., Reischl, M., Shah, A. H., Kronfuss, E., Mikut, R., Liebel, U., & Grabher, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137286 · Cited by 23 · see citing works

Phenotypic screening with primary neurons to identify drug targets for regeneration and degeneration

Cooper, D. J., Zunino, G., Bixby, J. L., & Lemmon, V. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2016.07.001 · Cited by 23 · see citing works

Intrinsic activity and positive feedback in motor circuits in organotypic spinal cord slice cultures

Magloire, V., & Streit, J. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06978.x · Cited by 21 · see citing works

In vivo phenotypic screening: clinical proof of concept for a drug repositioning approach

Ciallella, J. R., & Reaume, A. G. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.04.001 · Cited by 21 · see citing works

Potent suppression of stretch reflex activity after systemic or spinal delivery of tizanidine in rats with spinal ischemia-induced chronic spastic paraplegia

Fuchigami, T., Kakinohana, O., Hefferan, M. P., et al. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.022 · Cited by 19 · see citing works

Morphine-induced Straub tail reaction in mice treated with serotonergic compounds

Владимировна, Б. И., Драволина, О. А., Tur, M. А., et al. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.08.014 · Cited by 19 · see citing works

Novel insight into drug repositioning: Methylthiouracil as a case in point

Baek, M., Jung, B., Kang, H., Lee, H., & Bae, J. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.06.008 · Cited by 18 · see citing works

Functional regeneration of intraspinal connections in a new in vitro model

Heidemann, M., Streit, J., & Tscherter, A. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2013.12.051 · Cited by 16 · see citing works

Human Cerebrospinal Fluid Promotes Neuronal Viability and Activity of Hippocampal Neuronal Circuits In Vitro

Pérez-Alcázar, M., Culley, G. R., Lyckenvik, T., Mobarrez, K., Björefeldt, A., Wasling, P., Seth, H., Asztély, F., Harrer, A., Iglseder, B., et al. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00054 · Cited by 15 · see citing works

High content analysis in amyotrophic lateral sclerosis

Rinaldi, F., Motti, D., Ferraiuolo, L., & Kaspar, B. K. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2016.12.001 · Cited by 15 · see citing works

Two hundred years since James Parkinson's essay on the shaking palsy—Have we made progress? Insights from the James Parkinson's 200 years course held in London, March 2017

Chaudhuri, К. R., & Jenner, P. G. (2017) · Movement Disorders · doi:10.1002/mds.27104 · Cited by 10 · see citing works

A Practical Guide for Exploring Opportunities of Repurposing Drugs for CNS Diseases in Systems Biology

Mei, H., Feng, G., Zhu, J., Lin, S. M., Qiu, Y., Wang, Y., & Xia, T. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2627-5_33 · Cited by 7 · see citing works

theraTRACE®: a mechanism unbiased in vivo platform for phenotypic screening and drug repositioning

Saporito, M. S., & Reaume, A. G. (2011) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.06.002 · Cited by 6 · see citing works

The stress of misfolding

Yates, D. M. (2012) · Nature reviews. Neuroscience · doi:10.1038/nrn3235 · Cited by 3 · see citing works

From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology

Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179 · see citing works

Repurposed agents in the Alzheimer’s disease drug development pipeline

Bauzon, J., Lee, G., & Cummings, J. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00662-x · Cited by 77 · see citing works

Repurposing of the β-Lactam Antibiotic, Ceftriaxone for Neurological Disorders: A Review

Yimer, E. M., Hishe, H. Z., & Tuem, K. B. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00236 · Cited by 72 · see citing works

Treatment Repurposing using Literature-related Discovery

Kostoff, R. N. (2019) · Journal of Scientometric Research · doi:10.5530/jscires.8.2.25 · Cited by 4 · see citing works

A data-driven methodology towards evaluating the potential of drug repurposing hypotheses

Santamaría, L. P., Carro, E. U., Uzquiano, M. D., Menasalvas, E., Gallardo, Y. P., & Rodríguez‐González, A. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.003 · Cited by 22 · see citing works

The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions

Polamreddy, P., & Gattu, N. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.022 · Cited by 119 · see citing works

Drug Repurposing and Multi-Target Therapies

Kumar, A. P., Lukman, S., & Nguyen, M. N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.20160-x · Cited by 2 · see citing works

Faculty Opinions recommendation of Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns.

Rastelli, G., & Pinzi, L. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.740542384.793588144